Research Topics
| Puneeta TandonSummaryAffiliation: University of Alberta Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic valuePuneeta Tandon
Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada
Liver Transpl 18:1209-16. 2012..If this is validated in larger studies, the objective assessment of sarcopenia holds promise for prognostication in this patient population...
Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot studyPuneeta Tandon
Department of Medicine, University of Alberta, Edmonton, AB, Canada
Liver Int 29:1110-5. 2009..The objective of this study was to determine whether the probiotic VSL#3 would reduce portal pressure in patients with cirrhosis...
A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantationPuneeta Tandon
Department of Medicine, University of Alberta, Edmonton, Canada
Am J Gastroenterol 104:1700-6. 2009....
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot studyPuneeta Tandon
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Liver Int 29:169-74. 2009....
Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trialsP Tandon
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
Aliment Pharmacol Ther 25:1017-28. 2007..Although reversal of pretransplant renal dysfunction in hepatorenal syndrome reduces post-transplant complications, the overall impact on morbidity and mortality requires clarification...
The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experienceKarli J Moncrief
University of Alberta, Edmonton, Canada
Can J Gastroenterol 24:40-6. 2010..To describe the natural history of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) after liver transplant, the predictors of PSC and IBD recurrence, and the interaction of these disease processes...
Risk factors for recurrence of autoimmune hepatitis after liver transplantationAldo J Montano-Loza
Division of Gastroenterology and Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada
Liver Transpl 15:1254-61. 2009..These findings suggest that recurrence of autoimmune hepatitis may reflect incomplete suppression of disease activity prior to liver transplantation...
Alcohol use while on the liver transplant waiting list: a single-center experienceMichelle Carbonneau
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Liver Transpl 16:91-7. 2010..We hope that these measures will reduce the rate of relapse to alcohol use post-transplantation...
High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver centerPuneeta Tandon
University of Alberta, Edmonton, Alberta, Canada
Clin Gastroenterol Hepatol 10:1291-8. 2012..Exposure to systemic antibiotics is a risk factor for AR-BI; however, little is known about the effects of the increasingly used oral nonabsorbed antibiotics...
Cardiac work-up protocol for liver transplant candidates: experience from a single liver transplant centreCarrie Ye
Liver Unit, Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2X8, Canada
Can J Gastroenterol 26:806-10. 2012..Ischemic cardiac events can cause significant morbidity and mortality postliver transplantation; however, no validated protocols to screen patients before transplantation exist...
Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomesFinlay A McAlister
Division of General Internal Medicine, University of Alberta Hospital, Edmonton, Canada
Diabetes Care 26:1518-24. 2003..To determine the adequacy of perioperative glycemic control in diabetic patients undergoing coronary artery bypass grafting (CABG) and to explore the association between glycemic control and in-hospital morbidity/mortality...
Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varicesJ Cheung
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Canada
Aliment Pharmacol Ther 30:577-88. 2009..Variable methods are available for secondary prevention after oesophageal variceal bleeding (EVB)...
Bacterial infections, sepsis, and multiorgan failure in cirrhosisPuneeta Tandon
Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
Semin Liver Dis 28:26-42. 2008..We review the pathogenesis and management of these complications, the role of adrenal insufficiency, and the utility of intensive care prognostic models...
The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomesPuneeta Tandon
Division of General Internal Medicine, University of Alberta, Edmonton, Canada
Arch Intern Med 164:769-74. 2004..In our cohort of elderly patients with multiple comorbidities, beta-blockers were well tolerated...
Managing the post-liver transplantation anastomotic biliary stricture: multiple plastic versus metal stents: a systematic reviewDina Kao
Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Gastrointest Endosc 77:679-91. 2013..Covered self-expandable metal stents (SEMSs) have been increasingly used in this setting. However, it is not clear whether there are definite advantages of using SEMSs over MPSs...
The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritusPuneeta Tandon
Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
Am J Gastroenterol 102:1528-36. 2007..The objective of this review was to evaluate the efficacy and safety of rifampin, opioid antagonists, or bile acid binding agents in the treatment of cholestasis-related pruritus (CAP) from available randomized controlled trial evidence...
Use of angiotensin-converting enzyme inhibitors after coronary artery bypass grafting in patients with diabetes mellitusLana Bistritz
Division of General Internal Medicine, University of Alberta Hospital, Edmonton, Canada
Am J Cardiol 92:77-9. 2003
